The next most prescribed subgroups were M01AX that includes symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) and M01AH (selective cyclooxygenase-2 inhibitors or coxibs). This evidence concerns the gene PTGS2 and osteoarthritis.